Endoscopic treatment of reflux with deflux -tertiary care center experience

Volume : VIII, Issue : II, February - 2018

Dr Pradnya S Bendre, Dr. Amol Ramesh Nage, Dr. Flavia H Dsouza, Dr. Parag Karkera

Background. A number of bulking agents have been used for the endoscopic correction of

Vesicoureteral reflux in children. We present our long–term results of endoscopic use of

dextranomer/hyaluronic acid copolymer (Deflux®) for VUR treatment in children.

Patients and methods. Between 2014 and 2017, 40 children underwent endoscopic

subureteral injection of Deflux® in 50 ureters. 30 children had unilateral reflux

and 10 had bilateral reflux. Median age was 5–years (6–months to 14.9–years)

3month postoperatively, a voiding cystourethrogram was performed. Age, sex, grade of reflux and treatment results were recorded and evaluated.

Successful reflux correction was defined as downgrading or disappearance on follow–up VCUG

Results. No intra– or postoperative complications had been noticed. In 32 ureters (80%),

VCUG showed no VUR 3month postoperatively. Two children received a 2nd

Injection (two successful). In 6 ureter reflux persist(15%) & were converted to open surgery.

Conclusion. Endoscopic treatment of vesicoureteral reflux can be recommended as a

first–line therapy for most cases of vesicoureteral reflux, because of the short hospital

stay, absence of complications and the high success rate.